Antiapoptotic BCL2 family proteins BCL-XL and MCL1 as factors predicting resistance against venetoclax plus azacitidine for patients with newly diagnosed acute myelogenous leukemia
PLOS One · 2026
DOI: 10.1371/journal.pone.0341461 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS One, 2026. Verfasst von Yusuke Kamihara und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Toyama University School of Medicine, Toyama, Toyama, Japan. Hauptthemen laut MEDLINE: Sulfonamides, bcl-X Protein, Myeloid Cell Leukemia Sequence 1 Protein, Bridged Bicyclo Compounds, Heterocyclic. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japan Society for the Promotion of Science.
Abstract (Originalsprache)
The combination of Venetoclax (VEN), a BCL2 inhibitor, and Azacitidine (AZA), a hypomethylating agent, is the standard treatment for acute myelogenous leukemia (AML) in patients older than 65 years who are not eligible for intensive chemotherapy. While high response rates for this treatment have been noted, it has been also reported that the anti-apoptotic BCL2 family proteins BCL-XL and MCL1 may be involved in VEN resistance. However, no study has heretofore been conducted to investigate the effectiveness of treatment and the expression of BCL-XL or MCL1 in patients treated with VEN + AZA therapy. In this study, we analyzed blasts from patients with newly diagnosed AML treated with VEN + AZA therapy by qPCR, confirmed by siRNA in cultured cell lines, and evaluated the validity of the immunostaining method. We demonstrated that BCL-XL or MCL1 was highly expressed in leukemia cells of patients who did not respond to this treatment. In addition, leukemia cells from patients who had responded to VEN + AZA but relapsed during the course of treatment showed increased expression of BCL-XL or MCL1 compared to pre-treatment levels. Furthermore, downregulation of BCL-XL expression in a VEN-resistant AML cell line with siRNA increased sensitivity to VEN. On the other hand, the expression of BCL-XL and MCL1 in leukemia cells could be easily semi-quantified by immunostaining, with these results correlating with those obtained by qPCR. These results indicate that immunostaining for BCL-XL and MCL1 upon bone marrow examination at diagnosis not only can predict susceptibility to VEN + AZA therapy, but may also be useful for patient stratification for VEN + AZA treatment in the future.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Hematology, Toyama University School of Medicine, Toyama, Toyama, Japan.
- Division of Hematology/Oncology, University of Florida, Gainesville, Florida, United States of America.
ORCID-Profile: Yusuke Kamihara, Akinori Wada, Tsutomu Sato
Förderung
- Japan Society for the Promotion of Science
Zitieren
APA
Kamihara, Y., Kikuchi, S., Ishikawa, N., Shinomiya, N., Kunimoto, K., Horaguchi, R., Fujihira, T., Nabe, Y., Minemura, T., Ono, K., Wada, A., Dang, N. H., & Sato, T. (2026). Antiapoptotic BCL2 family proteins BCL-XL and MCL1 as factors predicting resistance against venetoclax plus azacitidine for patients with newly diagnosed acute myelogenous leukemia. PLOS One. https://doi.org/10.1371/journal.pone.0341461
Vancouver
Kamihara Y, Kikuchi S, Ishikawa N, Shinomiya N, Kunimoto K, Horaguchi R, et al. Antiapoptotic BCL2 family proteins BCL-XL and MCL1 as factors predicting resistance against venetoclax plus azacitidine for patients with newly diagnosed acute myelogenous leukemia. PLOS One. 2026. doi:10.1371/journal.pone.0341461
BibTeX
@article{Kamihara2026,
author = {Kamihara, Yusuke and Kikuchi, Shohei and Ishikawa, Nanako and Shinomiya, Nozomi and Kunimoto, Kohei and Horaguchi, Ryusuke and Fujihira, Takuma and Nabe, Yoshimi and Minemura, Tomoki and Ono, Kento and Wada, Akinori and Dang, Nam H and Sato, Tsutomu},
title = {Antiapoptotic BCL2 family proteins BCL-XL and MCL1 as factors predicting resistance against venetoclax plus azacitidine for patients with newly diagnosed acute myelogenous leukemia},
journal = {PLOS One},
year = {2026},
doi = {10.1371/journal.pone.0341461}
}
EUVIMED